SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:prod.swepub.kib.ki.se:135835034"
 

Search: onr:"swepub:oai:prod.swepub.kib.ki.se:135835034" > Efficacy of biologi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Nam, JL (author)

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2017-03-10
  • BMJ,2017

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:135835034
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:135835034URI
  • https://doi.org/10.1136/annrheumdis-2016-210713DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations.MethodsMEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained.ResultsThe RCTs confirmed greater efficacy with a bDMARD+conventional synthetic DMARD (csDMARD) versus a csDMARDs alone (level 1A evidence). Using a treat-to-target strategy approach, commencing and escalating csDMARD therapy and adding a bDMARD in cases of non-response, is an effective approach (1B). If a bDMARD had failed, improvements in clinical response were seen on switching to another bDMARD (1A), but no clear advantage was seen for switching to an agent with another mode of action. Maintenance of clinical response in patients in remission or low disease activity was best when continuing rather than stopping a bDMARD, but bDMARD dose reduction or ‘spacing’ was possible, with a substantial proportion of patients achieving bDMARD-free remission (2B). RCTs have also demonstrated efficacy of several new bDMARDs and biosimilar DMARDs (1B).ConclusionsThis systematic literature review consistently confirmed the previously reported efficacy of bDMARDs in RA and provided additional information on bDMARD switching and dose reduction.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Takase-Minegishi, K (author)
  • Ramiro, S (author)
  • Chatzidionysiou, KKarolinska Institutet (author)
  • Smolen, JS (author)
  • van der Heijde, D (author)
  • Bijlsma, JW (author)
  • Burmester, GR (author)
  • Dougados, M (author)
  • Scholte-Voshaar, M (author)
  • van Vollenhoven, RKarolinska Institutet (author)
  • Landewe, R (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Annals of the rheumatic diseases: BMJ76:6, s. 1108-11131468-20600003-4967

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view